Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 8/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | MC4R | P32245 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246244 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL3240154 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL3249270 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL3246423 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL6738195 | 0.87 | PTGS2 (0.77) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL6731769 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL4889613 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL3249585 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL6726349 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL3246332 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0927555-B1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia | DAIICHI SANKYO CO LTD (JP) | 2011-10-05 | — | — | EP | claimed |
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| EP-1061908-A4 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO INC (US) | 2007-01-24 | — | — | EP | claimed |
| US-7132441-B2 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. (US) | 2006-11-07 | — | — | US | claimed |
| EP-0880362-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4 RECEPTOR ANTAGONIST | SEARLE & CO (US) | 2005-05-25 | — | — | EP | claimed |
| US-20050043355-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | claimed |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2005-01-06 | — | — | US | claimed |
| EP-1024696-A4 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | claimed |
| US-20040106668-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | claimed |
| EP-1349548-A4 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO INC (US) | 2004-06-02 | — | — | EP | claimed |
| WO-1997029775-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1997011701-A1 | COMPOSITIONS FOR TREATING INFLAMMATION CONTAINING CERTAIN PROSTAGLANDINS AND A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | MERCK-FROSST CANADA INC. (CA) | 1997-04-03 | — | — | WO | claimed |
| EP-0758229-A1 | TOPICAL POLYMERIC DRUG DELIVERY SYSTEM | MERCK FROSST CANADA INC. (CA) | 1997-02-19 | — | — | EP | claimed |
| EP-0754687-A1 | Phenyl heterocycles as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC. (CA) | 1997-01-22 | — | — | EP | claimed |
| EP-0739340-A1 | PHENYL HETEROCYCLES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-10-30 | — | — | EP | claimed |
| EP-0705254-A1 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-04-10 | — | — | EP | claimed |
| US-5474995-A | Nonsteroidal, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1995-12-12 | — | — | US | claimed |
| WO-1995030409-A1 | TOPICAL POLYMERIC DRUG DELIVERY SYSTEM | MERCK FROSST CANADA INC. (CA) | 1995-11-16 | — | — | WO | claimed |
| WO-1995018799-A1 | PHENYL HETEROCYCLES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1995-07-13 | — | — | WO | claimed |
| WO-1995000501-A2 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1995-01-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106668-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin | LTB4R2, LTB4R, CYSLTR2 | PTGS2 9/4885PTGS1 14/4885ABCB11 3091/4885 |
| US-20050043355-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | LTA4H, LTB4R2, LTB4R | PTGS2 9/4885PTGS1 12/4885ABCB11 3035/4885 |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | ITGAV, ITGA5, ITGB5 | PTGS2 27/4885PTGS1 36/4885ABCB11 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.